Allogene Therapeutics ALLO Investment Income Net Amortization Of Discount And Premium
Investment Income Net Amortization Of Discount And Premium at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's investment income net amortization of discount and premium.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's investment income net amortization of discount and premium?
- Allogene Therapeutics (ALLO) reported investment income net amortization of discount and premium of $885K in Q1 2026.
- How has Allogene Therapeutics's investment income net amortization of discount and premium changed year-over-year?
- Allogene Therapeutics's investment income net amortization of discount and premium decreased by 32.2% year-over-year, from $1.31M to $885K.
- What is the long-term trend for Allogene Therapeutics's investment income net amortization of discount and premium?
- Over 4 years (2021 to 2025), Allogene Therapeutics's investment income net amortization of discount and premium has grown at a -11.7% compound annual growth rate (CAGR), from -$6.96M to $4.22M.
- What does investment income net amortization of discount and premium mean?
- This represents the net impact of interest income earned on cash equivalents and marketable securities, adjusted for the amortization of premiums or discounts on those investments. It reflects the non-cash component of investment returns that reconciles net income to operating cash flow. Investors use this to understand the yield generated from the company's treasury management activities.